A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
Key facts
- Who runs it
- Takeda
- Where
- Japan9 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT05513586
- JRCT2041220059
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 15 people enrolled
- Started
- 13 Sept 2022
- Ended
- 30 Oct 2025
- Type of study
- Interventional
- Treatments tested
- TAK-771
- Record updated
- 19 May 2026
Who can take part
- Age
- 2 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participant have completed or is about to complete Study TAK-771-3004 (NCT05150340)
- Written and/or electronic informed consent is obtained from either the participant or the participant's legally authorized representative prior to any study-related procedures and study product administration. If a participant is <18 years of age, written and/or electronic informed consent should also be obtained from the participant's legally authorized representative in addition to written informed assent by a participant if appropriate
- Participant is willing and able to comply with the requirements of the protocol
Who cannot take part
- Participant has developed a new serious medical condition during Study TAK-771-3004 such that the participant's safety or medical care would be impacted by participation in the study
- Participant is willing to participate in other clinical trials
- Women of childbearing potential who meet any one of the following criteria:; Participant presents with a positive pregnancy test; Participant does not agree to employ adequate birth-control measures (eg, intrauterine device, condom [for male partner], or birth-control pills) throughout the course of the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main aim of the study is to check side effect from the study treatment with TAK-771 in long term.
Read full original descriptionShow less
Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years.
There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.
The group in the trial
- TAK-771Treatment being tested
TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)
- Record updated
- 19 May 2026